MYDGF As A Telomerase Activator And Therapeutic Target For Osteoarthritis
Osteoarthritis is a widespread and debilitating joint condition where the protective cartilage in our joints breaks down, leading to pain and reduced mobility. Current treatments mainly focus on managing symptoms, as there are no approved drugs that can stop or reverse this cartilage degradation. However, new research has shed light on a promising molecule called myeloid-derived growth factor, or MYDGF. This protein has been found to be a key regulator of telomerase activity in chondrocytes, which are the cells responsible for maintaining cartilage. Telomerase is an enzyme that helps protect the ends of our chromosomes, called telomeres, from shortening. As cells divide, telomeres naturally get shorter, and critically short telomeres are associated with cellular aging and damage, particularly in cartilage. The study revealed that MYDGF not only boosts the activity of telomerase but also plays a vital role in maintaining the overall structure and health of cartilage. In experiments, mice that lacked MYDGF developed more severe cartilage damage, while introducing MYDGF into the knee joint actually helped protect the cartilage from injury. This discovery is significant because it links a naturally occurring protein to a fundamental cellular aging mechanism in cartilage, offering a new avenue for developing treatments that could potentially modify the course of osteoarthritis rather than just alleviating its symptoms.
Source: link to paper